Breast Cancer MRI: Screening and Detection

Breast cancer is the most common cancer in the UK, with around 56,000 new diagnoses each year. Breast MRI is the most sensitive imaging test for detecting breast cancer, picking up approximately 95% of invasive cancers compared to around 85% for mammography and 80% for ultrasound. It is not used as a routine screening tool for the general population, but it is essential for high-risk screening, assessing the extent of known cancer, and solving diagnostic problems that mammography and ultrasound cannot resolve.

If you are at high risk of breast cancer, have a known cancer that needs further assessment, or have a breast problem that other imaging has not been able to characterise, a breast MRI provides the most detailed view available.

When Breast MRI Is Used

Breast MRI is not a first-line investigation for most breast problems. It is specifically recommended for:

High-Risk Screening

The NHS Breast Screening Programme offers annual MRI to women at very high risk:

• Known BRCA1 or BRCA2 gene mutation carriers — from age 30
• TP53 mutation carriers (Li-Fraumeni syndrome) — from age 20
• Women at 30%+ lifetime risk based on family history models
• Previous chest wall radiotherapy (e.g. for Hodgkin lymphoma) — from 8 years after treatment

MRI detects cancers in these high-risk groups that mammography misses, particularly in younger women with dense breast tissue where mammography performs poorly.

Assessment of Known Cancer

• Local staging — determining the exact size of a known cancer and whether there are additional cancer foci (multifocal or multicentric disease) that mammography and ultrasound have not shown. MRI changes the surgical plan in 15-30% of cases.
• Contralateral breast check — checking the opposite breast for synchronous cancer. Found in 3-5% of newly diagnosed patients.
• Lobular carcinoma assessment — invasive lobular carcinoma (ILC) is notoriously underestimated by mammography and ultrasound. MRI is far more accurate for assessing ILC extent.
• Neoadjuvant chemotherapy monitoring — tracking tumour size during pre-operative chemotherapy. MRI is the most accurate test for assessing treatment response and residual tumour size.

Problem-Solving

• Discrepancy between clinical findings and mammography/ultrasound results
• Axillary lymph node metastasis with no primary breast cancer found on mammography or ultrasound (occult primary)
• Post-surgical assessment when mammography/ultrasound findings are equivocal
• Breast implant assessment (implant integrity and screening around implants)

What Breast MRI Shows

Breast MRI uses gadolinium contrast and dynamic imaging (taking images at intervals after injection) to detect cancer based on its blood supply pattern:

• Enhancement pattern — cancers typically enhance rapidly and then wash out (type III kinetics). Benign lesions tend to enhance progressively (type I kinetics). Type II (plateau) is intermediate.
• Morphology — irregular masses with spiculated margins and heterogeneous enhancement are suspicious. Smooth, well-defined, homogeneous lesions are more likely benign.
• Non-mass enhancement (NME) — an area of enhancement without a distinct mass. Can represent DCIS (ductal carcinoma in situ), ILC, or benign changes. Pattern and distribution guide management.
• BI-RADS scoring — breast MRI findings are scored using the BI-RADS (Breast Imaging Reporting and Data System) classification:
  • BI-RADS 1: Normal
  • BI-RADS 2: Benign finding
  • BI-RADS 3: Probably benign (less than 2% chance of cancer). Short-term follow-up recommended.
  • BI-RADS 4: Suspicious. Biopsy recommended. (Subdivided 4A, 4B, 4C by suspicion level.)
  • BI-RADS 5: Highly suggestive of malignancy. Biopsy required.
  • BI-RADS 6: Known cancer (being scanned for staging or treatment monitoring).
• DWI (diffusion-weighted imaging) — increasingly used alongside dynamic contrast. Cancer cells restrict water diffusion, appearing bright on DWI with low ADC values. Improves specificity.

What to Expect During a Breast MRI

A breast MRI takes 30-45 minutes. The experience is different from a standard MRI:

1. Positioning — you lie face down on a special table with openings for your breasts to hang into cushioned apertures. This gives the best image quality and is more comfortable than it sounds.
2. Compression — the breasts are gently held in place within the coil. Less compression than a mammogram.
3. Contrast injection — gadolinium is injected through a cannula in your arm partway through the scan. Multiple images are taken before and after injection to capture the enhancement pattern.
4. Timing — ideally performed during days 7-14 of your menstrual cycle (if pre-menopausal). Hormonal changes around menstruation can cause benign breast tissue enhancement that mimics cancer, leading to false-positive findings.

Preparation

• Kidney function test (eGFR) usually required for contrast
• Wear comfortable clothing without metal — you will change into a gown
• Remove all jewellery and piercings
• Inform the team if you have breast implants

What Breast MRI Cannot Do

• Detect microcalcifications — tiny calcium deposits that can indicate DCIS. Mammography is better for these. This is why MRI does not replace mammography — they are complementary.
• Distinguish between all benign and malignant lesions — breast MRI has high sensitivity but lower specificity than mammography. This means it finds more cancers but also produces more false positives (benign lesions that look suspicious). Biopsy is needed for definitive diagnosis.
• Replace mammographic screening for average-risk women — the false-positive rate, cost, and need for contrast mean MRI is not suitable for population-level screening.

Alternative and Complementary Tests

• Mammography — the standard screening test. X-ray-based. Detects 85% of breast cancers. Best for microcalcifications and architectural distortions. Digital breast tomosynthesis (3D mammography) improves accuracy in dense breasts.
• Ultrasound — first-line for palpable lumps in women under 40 and as an adjunct to mammography. Good for distinguishing cysts from solid masses. No radiation.
• Contrast-enhanced spectral mammography (CESM) — mammography with iodinated contrast. Provides some of the contrast information of MRI with the convenience and speed of mammography. Emerging modality.
• Biopsy — core needle biopsy (under ultrasound, stereotactic, or MRI guidance) for definitive tissue diagnosis. MRI-guided biopsy (MRI bx) is used for lesions only visible on MRI.

Treatment Pathways

• Surgery — wide local excision (lumpectomy) + radiotherapy for early-stage cancer. Mastectomy for larger or multifocal cancers. Sentinel lymph node biopsy to check for spread. Breast reconstruction options available.
• Radiotherapy — standard after lumpectomy. Reduces recurrence risk by 50-66%.
• Chemotherapy — for larger tumours (neoadjuvant, before surgery), high-risk tumours (adjuvant, after surgery), or metastatic disease.
• Hormone therapy — for ER-positive cancers (approximately 75% of breast cancers). Tamoxifen or aromatase inhibitors for 5-10 years.
• HER2-targeted therapy — trastuzumab (Herceptin) and pertuzumab for HER2-positive cancers (approximately 15%).
• Follow-up — annual mammography. MRI follow-up in specific circumstances (high risk, breast implants, neoadjuvant chemotherapy response assessment).

UK Statistics

• Around 56,000 women are diagnosed with breast cancer each year in the UK
• 1 in 7 women will develop breast cancer in their lifetime
• 5-year survival: 87% overall; 98% for stage 1
• NHS Breast Screening Programme invites women aged 50-71 for mammography every 3 years
• 5-12% of breast cancers occur in women with known genetic mutations (BRCA1/BRCA2)
• Approximately 400 men are diagnosed with breast cancer each year in the UK

Frequently Asked Questions

Related Articles

• Can an MRI Detect Cancer?
• Ovarian Cyst MRI
• Endometriosis MRI